Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials.
Invest Radiol
; 23 Suppl 1: S281-5, 1988 Sep.
Article
em En
| MEDLINE
| ID: mdl-3058632
ABSTRACT
The preclinical and clinical trial experience with ferrioxamine (S-FDF; Salutar, Inc.) as a contrast agent for magnetic resonance imaging (MRI) is summarized. The results in 44 patients or subjects show that the drug is safe and well tolerated when given intravenously. In certain conditions, early results show that the use of this contrast agent provides more information than can be obtained with MRI alone.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Imageamento por Ressonância Magnética
/
Compostos Férricos
/
Quelantes de Ferro
/
Meios de Contraste
/
Desferroxamina
Idioma:
En
Ano de publicação:
1988
Tipo de documento:
Article